share_log

Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30

Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30

高盛以買入評級啓動對Mineralys Therapeutics的報道,宣佈目標股價爲30美元
Moomoo 24/7 ·  04/02 07:10

Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.

高盛分析師理查德·勞開始對Mineralys Therapeutics(納斯達克股票代碼:MLYS)進行報道,評級爲買入,並宣佈目標股價爲30美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論